Trial Profile

A Randomized, Investigator and Subject Blinded, Multicenter, Parallel-arm Study to Determine the Safety and Tolerability of Tropifexor.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tropifexor (Primary)
Indications Liver disorders; Non-alcoholic steatohepatitis
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

Most Recent Events

15 Nov 2021 Results investigating the impact of evening vs morning dosing of Tropifexor on bile acids profile in patients with nonalcoholic steatohepatitis, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
30 Apr 2021 Status changed from recruiting to completed.
11 Aug 2020 Planned End Date changed from 12 May 2021 to 31 Mar 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com